The association between fluconazole dose and MIC with mortality and persistence in candidemia
Ghanem-Zoubi N, Qasum M, Khoury J, Zorbavel D, Arnon M, Geffen Y, Paul M. The association between fluconazole dose and MIC with mortality and persistence in candidemia. European Journal Of Clinical Microbiology & Infectious Diseases 2019, 38: 1773-1780. PMID: 31197619, DOI: 10.1007/s10096-019-03611-1.Peer-Reviewed Original ResearchConceptsAUC24/MICClinical outcomesC. glabrata candidemiaComposite of mortalityExposure parametersLowest MIC valueSimilar non-significant differencesFluconazole doseFluconazole dosingPersistent candidemiaSingle centerMIC valuesClinical failureInclusion criteriaCandidemiaPatientsDay 14Non-significant differenceHigh MICsFluconazole MICsStudy periodMortalityCandida speciesMICC. glabrataRisk Factors for Non-Albicans Candidemia Focusing on Prior Antifungal and Immunosuppressive Therapy.
Ghanem-Zoubi N, Khoury J, Arnon M, Zorbavel D, Geffen Y, Paul M. Risk Factors for Non-Albicans Candidemia Focusing on Prior Antifungal and Immunosuppressive Therapy. Israel Medical Association Journal 2019, 21: 303-307. PMID: 31140219.Peer-Reviewed Original ResearchConceptsBlood stream infectionsSignificant risk factorsRisk factorsImmunosuppression therapyImmunosuppressive therapySignificant independent risk factorsRambam Health Care CampusCandida blood stream infectionEpisodes of candidemiaRetrospective cohort studyIndependent risk factorTertiary medical centerSubgroup of patientsBone marrow transplantationHealth Care CampusNon-albicans candidemiaNAC candidemiaNAC sppAdult patientsCohort studyMarrow transplantationClinical manifestationsMedical CenterCandidemiaPatients